MANKIND PHARMACEUTICALS LTD

The revenue generation for New Delhi-based Mankind Pharmaceuticals was recorded at Rs 60 crore in the biopharma space during FY 20-21, showing a slight growth of 3 per cent in comparison to the revenue figure in FY 19-20 which stood at Rs 58 crore. The year 2020 saw the company entering into collaboration with South Korea-based Daewoong Pharmaceutical for conducting Phase I clinical trial of a long-acting intramuscular formulation of Niclosamide against COVID-19. Mankind has over 1000 products being marketed and more than 200 products under development.